Just two months ago, the incredible performance of new vaccines from Moderna and Pfizer had people cheering for an imminent end to the pandemic. But an onslaught of fast-spreading and potentially dangerous mutations of the virus changed that.
So now, even as pharma companies ramp up production in the early stages of a massive rollout, they are racing to retool their vaccine strategies. Robert Langreth reports that booster shots could give drugmakers a lucrative new revenue stream.
On the first day of former President Donald Trump’s second impeachment trial, the Senate voted that the trial of a former president is constitutional, setting up days of arguments from House managers and Trump’s defense team.
Also, the U.S. military will pause normal operations to examine the problem of domestic extremism within the military ranks. And, Twitter is testing a new pilot program to try and get the spread of misinformation on the platform under control.
Democrats’ plan offers $1,400 stimulus checks at same income levels as previous rounds, Former President Trump’s lawyers call impeachment trial political theater, Cincinnati ‘tip war’ raises over $34,000 for restaurant workers in hometown rivalry.
The second impeachment trial of former President Donald Trump begins this week as Republicans and his legal team argue the impeachment is unconstitutional.
And, South Africa has paused a planned deployment of a coronavirus vaccine from AstraZeneca after a study there showed it may be less effective against a new strain of the virus detected there. Also, how worried are U.S. health officials about variant strains of the virus in the U.S.?
The weekend’s biggest talking points are dissected by Tyler Brûlé, Christoph Lenz, Benno Zogg, Chiara Rimella and Jan E Brucker, with commentary from our editors in London and Tokyo. Plus: what is on the pages of ‘The National’ newspaper in the UAE?
Georgina Godwin covers the weekend’s biggest discussion topics. We flick through the weekend’s papers with Terry Stiastny, Andrew Mueller recaps the week’s biggest lessons and we hear editor in chief Andrew Tuck’s Saturday column.
Researchers are scrambling to understand the biology of new coronavirus variants and the impact they might have on vaccine efficacy.
Around the world, concern is growing about the impact that new, faster-spreading variants of the SARS-CoV-2 virus will have on the pandemic.
In this episode of Coronapod, we discuss what these variants are, and the best way to respond to them, in the face of increasing evidence that some can evade the immunity produced by vaccination or previous infection.
News: ‘A bloody mess’: Confusion reigns over naming of new COVID variants
News: Fast-spreading COVID variant can elude immune responses
News: Could new COVID variants undermine vaccines? Labs scramble to find out
News: How to redesign COVID vaccines so they protect against variants
News: J&J’s one-shot COVID vaccine offers hope for faster protection
President Biden announced the U.S. will no longer support offensive military operations led by Saudi Arabia in Yemen, reversing a policy started by the Obama administration.
And, a new model by researchers at Columbia University paints what they say is a more accurate picture of the spread of the pandemic. Also, voting technology company Smartmatic is suing Fox News and some of its biggest stars alleging they spread disinformation that devastated the company.
This week we’re dedicating the whole show to the 20th anniversary of the publication of the human genome. Today, about 30 million people have had their genomes sequenced. This remarkable progress has brought with it issues of data sharing, privacy, and inequality.
Host Sarah Crespi spoke with a number of researchers about the state of genome science, starting with Yaniv Erlich, from the Efi Arazi School of Computer Science and CEO of Eleven Biotherapeutics, who talks about privacy in the age of easily obtainable genomes. Next up Charles Rotimi, director of the Center for Research on Genomics and Global Health at the National Human Genome Research Institute, discusses diversity—or lack thereof—in the field and what it means for the kinds of research that happens. Finally, Dorothy Roberts, professor in the departments of Africana studies and sociology and the law school at the University of Pennsylvania, talks about the seemingly never-ending project of disentangling race and genomes.
A.M. Edition for Feb. 4. A hedge fund made nearly $700 million in the GameStop rally. Consulting giant McKinsey reaches a settlement centering on opioid painkillers.
Plus, WSJ economics reporter Kate Davidson previews coming jobs data. Marc Stewart hosts.
Boomers Daily 